Cargando…

Factors Associated with Costs in Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies

BACKGROUND: Chimeric antigen receptor T cells (CAR-Ts) constitute a novel therapeutic strategy for relapsed/refractory B-cell malignancies. CAR-T therapy has been extensively applied in the clinical setting; however, few systematic studies have evaluated the cost of CAR-T treatment. This study was c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Feng, Wei, Guoqing, Zhang, Mingming, Zhao, Houli, Wu, Wenjun, Yang, Luxin, Hu, Yongxian, Huang, He
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444226/ https://www.ncbi.nlm.nih.gov/pubmed/32314613 http://dx.doi.org/10.1177/0963689720919434

Ejemplares similares

Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-cell Malignancies
por: Zhu, Feng, et al.
Publicado: (2021)

Idiopathic thrombocytopenic purpura treatment in a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T cell therapy
por: Qiu, Lei, et al.
Publicado: (2020)

Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma
por: Zu, Cheng, et al.
Publicado: (2022)

Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant Relapse
por: Ding, Lijuan, et al.
Publicado: (2021)

Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
por: Wei, Guoqing, et al.
Publicado: (2017)

A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
por: Wang, Yiyun, et al.
Publicado: (2020)

Delayed Terminal Ileal Perforation in a Relapsed/Refractory B-Cell Lymphoma Patient with Rapid Remission Following Chimeric Antigen Receptor T-Cell Therapy
por: Hu, Yongxian, et al.
Publicado: (2018)

Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy
por: Hong, Ruimin, et al.
Publicado: (2020)

Clinical Characterization and Risk Factors Associated with Cytokine Release Syndrome Induced By COVID-19 and Chimeric Antigen Receptor T-Cell Therapy
por: Hong, Ruimin, et al.
Publicado: (2020)

Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma
por: Zhang, Qiqi, et al.
Publicado: (2023)

Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma
por: Potnis, Kunal C., et al.
Publicado: (2022)

Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer
por: Ding, Jing, et al.
Publicado: (2022)

P1466: CD7 CHIMERIC ANTIGEN RECEPTOR T CELLS FOR ADULT PATIENTS WITH REFRACTORY AND RELAPSED T CELL MALIGNANCIES
por: Zhang, Y., et al.
Publicado: (2022)

Tumor Burden Measured by 18F-FDG PET/CT in Predicting Efficacy and Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma
por: Hong, Ruimin, et al.
Publicado: (2021)

Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma
por: Zhou, Jin, et al.
Publicado: (2022)

Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care
por: Cummings Joyner, Alice Kate, et al.
Publicado: (2022)

Cytokine Release Syndrome Is an Independent Risk Factor Associated With Platelet Transfusion Refractoriness After CAR-T Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia
por: Liu, Yadan, et al.
Publicado: (2021)

Lymphodepletion chemotherapy revitalizes chimeric antigen receptor T cells contributing to regression of relapsed B-cell lymphoma: A case report
por: Liang, Zuyu, et al.
Publicado: (2020)

Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma
por: Zhang, Lina, et al.
Publicado: (2021)

New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
por: Wang, Linqin, et al.
Publicado: (2021)

Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma
por: Wu, Jiaying, et al.
Publicado: (2022)

Successful treatment of relapsed acute B-cell lymphoblastic leukemia with CD20/CD22 bispecific chimeric antigen receptor T-cell therapy
por: Liang, Zuyu, et al.
Publicado: (2020)

Nursing care of patients with relapsed and refractory multiple myeloma treated with B-cell mature antigen-targeted universal chimeric antigen receptor T cells
por: Dai, Ying, et al.
Publicado: (2023)

Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL
por: Song, Fengmei, et al.
Publicado: (2023)

Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy
por: Zhang, Mingming, et al.
Publicado: (2021)

Chimeric Antigen Receptor Therapy for B-cell Malignancies
por: Porter, David L, et al.
Publicado: (2011)

Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment
por: Zhou, Linghui, et al.
Publicado: (2021)

Pleural cavity cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy: A case report
por: Ding, Lijuan, et al.
Publicado: (2018)

Chimeric Antigen Receptors for T-Cell Malignancies
por: Scherer, Lauren D., et al.
Publicado: (2019)

The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis
por: Zhou, Hui, et al.
Publicado: (2018)

Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma
por: Lin, Richard J., et al.
Publicado: (2020)

Bridging chimeric antigen receptor T-cell before transplantation improves prognosis of relapsed/refractory B-cell acute lymphoblastic leukemia
por: Zhao, Xiangyu, et al.
Publicado: (2023)

Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies
por: Xie, Danni, et al.
Publicado: (2022)

Cost‐effectiveness of Anti‐CD19 chimeric antigen receptor T‐Cell therapy in pediatric relapsed/refractory B‐cell acute lymphoblastic leukemia. A societal view
por: Thielen, Frederick W., et al.
Publicado: (2020)

Recent progress in improving the safety and efficacy of chimeric antigen receptor T cell therapy
por: Yang, Yingying, et al.
Publicado: (2018)

Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma
por: Lyman, Gary H., et al.
Publicado: (2020)

Chylothorax after chimeric antigen receptor T cell therapy for relapsed and refractory diffuse large B-cell lymphoma: A case report
por: Chen, Hsin-Hui, et al.
Publicado: (2023)

Effectiveness and safety of CD22 and CD19 dual‐targeting chimeric antigen receptor T‐cell therapy in patients with relapsed or refractory B‐cell malignancies: A meta‐analysis
por: Nguyen, Thi Thuy, et al.
Publicado: (2023)

Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma
por: Cao, Yaqing, et al.
Publicado: (2019)

Profile of capillary-leak syndrome in patients received chimeric antigen receptor T cell therapy
por: Feng, Jingjing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gi8oij49n4a06numgt7ea6ovud